LABCORP HOLDINGS Business Summary

Labcorp Holdings Inc. (LH) operates as a premier global life sciences leader, generating revenue through a high-volume, fee-for-service model across two primary segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Dx segment, which accounts for approximately 78% of total revenue, provides a comprehensive suite of routine and specialty testing services through a vast network of patient service centers and hospital partnerships. The BLS segment offers end-to-end support for the pharmaceutical and biotechnology industries, including central laboratory services and early-stage research. Following the 2023 spin-off of its clinical development business (Fortrea), Labcorp has solidified its position as a "pure-play" laboratory powerhouse, projecting 2026 revenues between $14.6 billion and $14.8 billion. The company competes directly with Quest Diagnostics, Eurofins Scientific, and Sonic Healthcare, maintaining a dominant market share in the U.S. clinical lab space through its massive scale, integrated data analytics, and an expanding specialty testing portfolio in oncology and neurology. The company is led by Chairman and CEO Adam H. Schechter, a veteran healthcare executive who joined Labcorp in 2019 after a 31-year tenure at Merck & Co., where he served as President of Global Human Health. The executive team includes Executive Vice President and CFO Julia Wang, who oversees the firm's financial strategy and capital allocation, and Chief Information and Technology Officer Bola Oyegunwa, Ph.D., who leads digital innovation and AI-driven diagnostic initiatives. Scientific and medical leadership is provided by Dr. Brian Caveney, who serves as Chief Medical and Scientific Officer. While the company traces its origins to the 1969 founding of Biomedical Reference Laboratories by the Powell brothers, its modern governance is supported by a high-profile Board of Directors, recently bolstered by the February 2026 appointment of Dr. John H. Sampson (Dean of the University of Colorado School of Medicine) and the late 2025 addition of Victor Bulto (President of Novartis US). Major institutional investors include The Vanguard Group and BlackRock, reflecting Labcorp's status as a core S&P 500 healthcare constituent.